Pain Sensitivity and Your Genetics

Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder Reviewed by ExomeDNA Editorial Process Last reviewed: May 26, 2026

Pain sensitivity — how broadly and intensely the nervous system perceives and sustains pain — has a substantial genetic component that is shared across multiple chronic pain conditions simultaneously. CELF4, FOXP2, and DCC are among the highest-confidence genetic signals for the general pain factor, a novel genomic construct capturing shared heritable variance across 24 distinct chronic pain conditions in up to 436,000 UK Biobank participants, with enrichment in brain tissues and genetic overlap with cognition, mood, and brain structure.^[1] Below: how inherited variation in neural development and processing biology shapes general pain susceptibility, and what the evidence reveals about the genetics of this trait.

What is the general pain factor?

Chronic pain is not a single condition — it encompasses musculoskeletal pain (back, neck, hip, knee), headache and migraine, gastrointestinal pain, pelvic pain, and many other forms that differ in mechanism, location, and clinical presentation. Yet these seemingly distinct conditions share a striking genetic overlap: the same inherited variants that increase susceptibility to back pain also partly predict risk for headache, fibromyalgia, and GI pain. This shared heritable component is the general pain factor.

Genomic structural equation modeling — a technique that extracts latent genetic factors from the shared variance across multiple traits — was applied to 24 chronic pain conditions in the UK Biobank, identifying a general factor explaining common genetic variance across all pain categories and a second factor specific to musculoskeletal pain. Network analysis identified arthropathic, back, and neck pain as central hubs — the conditions with the most extensive genetic connections to other pain conditions in the network.

The general pain factor does not correspond to any single pain mechanism. Instead, it likely captures heritable differences in how the nervous system processes, amplifies, and sustains pain signals — a phenomenon known as central sensitization. Individuals with higher central sensitization tendency develop chronic pain more readily across multiple pain conditions, and the general pain factor genetics points toward the neural circuit development and neural signaling biology that underlies this sensitization threshold.

The genetics of pain sensitivity

The genetic architecture of the general pain factor reflects neural biology — brain tissue enrichment in functional annotation, and genetic overlap with cognition and mood — consistent with central (brain and spinal cord) rather than purely peripheral (nociceptor) mechanisms. CELF4, FOXP2, MLN, DCC, and CA10 are among the highest-confidence signals in fine-mapped genetic data for this trait.^[1]

Up to 436,000 UK Biobank participants were analyzed across 24 chronic pain conditions using genomic structural equation modeling (Zorina-Lichtenwalter et al. 2023, Pain), identifying a general genetic factor explaining shared variance across all chronic pain categories — with enrichment in brain tissues and genetic connections to cognition, mood, and brain structure, pointing toward central nervous system biology as the primary mediator of inherited cross-condition pain susceptibility.^[1]

CELF4 — CUGBP ELAV-like family member 4 — is the top-ranked genetic signal for the general pain factor. CELF4 is an RNA-binding protein that regulates mRNA splicing and translation in neurons throughout the central and peripheral nervous system. As a master regulator of RNA processing in neural tissues, CELF4 shapes the expression of neuronal proteins involved in synaptic function, ion channel activity, and neural plasticity. Its emergence as a pain factor locus is consistent with the hypothesis that inherited variation in neural RNA processing programs shapes the threshold for central pain sensitization — altering how neurons respond to and amplify pain input.

FOXP2 — forkhead box P2 — is a transcription factor primarily known for its role in speech and language development: FOXP2 mutations cause severe developmental verbal dyspraxia. However, FOXP2 is broadly expressed during neurodevelopment in cortical, subcortical, and cerebellar regions and regulates the development of neural circuits far beyond language areas. Its appearance in pain genetics likely reflects its role in shaping sensory and motor circuit connectivity during development — circuits that overlap with those processing and modulating pain in adulthood.

A musculoskeletal-specific genetic factor was also identified alongside the general pain factor in the same 24-condition analysis, with arthropathic, back, and neck pain as central network hubs — demonstrating that inherited chronic pain susceptibility has both universal (general factor, enriched in brain) and condition-specific (musculoskeletal factor) genetic dimensions that can be statistically distinguished.^[1]

DCC — deleted in colorectal carcinoma — is a transmembrane receptor for netrin-1 that guides axon development during nervous system formation. DCC is expressed in dorsal horn neurons, corticospinal axons, and commissural interneurons involved in pain processing circuits. Netrin-DCC signaling directs the axonal projections of pain-processing neurons in the spinal cord, and DCC mutations cause congenital mirror movements (unintended mirroring of voluntary arm movements) reflecting disrupted motor circuit development. DCC's presence in pain genetics is consistent with inherited variation in the axonal connectivity of pain-processing circuits shaping long-term central pain sensitivity.

CA10 — carbonic anhydrase 10 — encodes a brain-expressed protein in the CA family that is catalytically inactive (does not catalyze CO2 hydration) but modulates synaptic signaling by binding sulfated ligands and interacting with neurexins to influence synaptic organization. MLN (motilin), a peptide hormone expressed in the duodenum that regulates gastrointestinal motility via the enteric nervous system and gut-brain axis, may reflect the visceral pain dimension of the general pain factor — GI pain conditions including IBS are among the 24 conditions studied.

What the research says

Research base: Moderate. The genetic architecture of the general pain factor is supported by genomic structural equation modeling of 24 chronic pain conditions in up to 436,000 UK Biobank participants (Zorina-Lichtenwalter et al. 2023, Pain).^[1] The study identified a statistically robust general factor with brain tissue enrichment and cognitive/mood genetic correlations — a meaningful finding that advances the genetic understanding of shared chronic pain susceptibility. Moderate confidence reflects the methodological novelty of the pain factor construct (replicated factor structure is still being established across cohorts) and the European-ancestry focus of the UK Biobank. See our methodology page for how we evaluate and apply genetic evidence in your ExomeDNA profile.

How pain sensitivity genetics affects health

The general pain factor captures an inherited tendency toward broad pain sensitivity — a lower threshold for developing and maintaining chronic pain across multiple conditions simultaneously. People with higher general pain factor scores are more likely to report pain at multiple body sites, to transition from acute to chronic pain following injury, and to develop overlapping pain conditions over time.

The genetic overlap with cognition, mood, and brain structure found in Zorina-Lichtenwalter et al. 2023 reflects the well-documented relationship between pain and psychological factors. Depression, anxiety, and cognitive function all bidirectionally interact with chronic pain — individuals with chronic pain are at elevated risk for mood disorders, and psychological vulnerability can amplify pain perception through descending pain modulation pathways. The brain-enriched genetics of the general pain factor suggests these are not merely psychological reactions to pain but shared neural substrates that shape both pain sensitivity and mood/cognitive functioning.

A higher genetic risk score for pain sensitivity reflects greater inherited susceptibility to cross-condition chronic pain — not certainty of developing chronic pain. Environmental exposures (injury, stress, sleep deprivation), lifestyle factors, and psychological resilience substantially determine whether genetic susceptibility translates into chronic pain burden.

Working with your pain sensitivity result

What research suggests about pain sensitivity management

• Sleep prioritization: sleep deprivation lowers pain thresholds measurably and is among the most consistently replicated environmental modulators of pain sensitivity; individuals with higher genetic pain susceptibility may be especially affected by sleep deficits.^[1]
• Regular aerobic exercise: exercise consistently reduces chronic pain across conditions through central analgesic mechanisms — exercise-induced endogenous opioid release, reduced inflammation, and improved mood all contribute to reduced chronic pain burden.
• Stress management and psychological support: given the brain-enriched genetics and overlap with mood disorders, psychological interventions (CBT, mindfulness-based stress reduction) have evidence for reducing chronic pain severity independent of the peripheral pain source.
• Early pain management: the transition from acute to chronic pain is partly governed by central sensitization genetics; prompt evidence-based management of acute pain episodes may reduce the probability of central sensitization becoming established.
• Multidisciplinary approaches: the general pain factor genetics — spanning brain development, mood, and cognition — is consistent with the clinical evidence that interdisciplinary pain programs (combining physical therapy, psychology, and medical care) outperform single-modality interventions for chronic cross-condition pain.
• Inflammatory monitoring: given the genetic overlap with musculoskeletal conditions and inflammation, monitoring and managing systemic inflammation (through diet, exercise, and appropriate medical care) addresses a modifiable contributor to pain burden.

Related traits and genes

Pain sensitivity genetics connects broadly across the ExomeDNA profile. Chronic Back Pain Risk and Fibromyalgia Risk represent specific chronic pain conditions whose genetic architecture partly overlaps with the general pain factor. Migraine Risk is among the 24 pain conditions in the Zorina-Lichtenwalter analysis and shares neural sensitization biology with the general pain factor.

Within brain biology, Depression Risk and Anxiety Disorder Risk share genetic overlap with the general pain factor through the brain-enriched genetic architecture — the same neural circuits that predispose to chronic pain also intersect with mood regulation. Sleep Quality connects bidirectionally: sleep disruption amplifies pain sensitivity, and chronic pain disrupts sleep.

Frequently asked questions

What is the general pain factor and what does a higher score mean?

The general pain factor is a latent genetic construct extracted from the shared heritable variance across 24 distinct chronic pain conditions simultaneously. It represents inherited susceptibility to pain broadly — a tendency toward lower pain thresholds and greater pain persistence across multiple condition types rather than susceptibility to any single pain condition. A higher genetic score reflects greater inherited contribution to this general pain sensitivity, translating to higher population-level probability of developing cross-condition chronic pain over the lifespan.

What does CELF4 do and why does it appear in pain genetics?

CELF4 is an RNA-binding protein that regulates mRNA splicing and translation throughout the nervous system. As a master regulator of neural RNA processing, CELF4 shapes the expression of synaptic proteins, ion channels, and neural plasticity factors that collectively determine how neurons respond to and sustain pain signals. Inherited variation in CELF4 may shift the threshold for central sensitization — the process by which the nervous system amplifies and perpetuates pain signals — which is a key mechanism underlying cross-condition chronic pain susceptibility.

Why does FOXP2 — a language gene — appear in pain genetics?

FOXP2 is primarily known for its role in speech and language development, but it is a transcription factor broadly expressed during neurodevelopment in cortical, subcortical, and cerebellar regions that also contribute to sensory processing. FOXP2 regulates the development of neural circuits across many brain regions, not just language areas. Its presence in pain genetics likely reflects inherited variation in sensory and pain circuit connectivity that emerges during brain development — consistent with the general pain factor's enrichment in brain tissue rather than peripheral nociception.

What is DCC and how does it relate to pain biology?

DCC is a receptor for the axon guidance molecule netrin-1, critical for directing axon growth and connectivity during nervous system development. DCC is expressed in dorsal horn neurons, corticospinal projections, and commissural interneurons — circuits central to pain signal processing and modulation in the spinal cord. Inherited variation in DCC affecting the connectivity of pain-processing circuits during development may shift the organization of the pain modulation network, contributing to individual differences in pain threshold and chronification susceptibility across multiple pain conditions.

Is the general pain factor the same as fibromyalgia?

No. Fibromyalgia is a specific clinical syndrome characterized by widespread musculoskeletal pain, fatigue, and cognitive symptoms — it is one of the 24 conditions whose shared genetic variance the general pain factor summarizes. The general pain factor is a broader statistical construct representing the genetic component shared across all 24 chronic pain conditions, including musculoskeletal, headache, GI, and other pain types. It captures the inherited neural substrate of broad pain sensitivity rather than a specific clinical condition. An individual with a high general pain factor score may or may not develop fibromyalgia specifically.

References

1. Zorina-Lichtenwalter K, et al. (2023). Genetic risk shared across 24 chronic pain conditions: identification and characterization with genomic structural equation modeling. Pain. PMID: 37219871. DOI: 10.1097/j.pain.0000000000002922.

Data sources:

• GWAS Catalog (NHGRI-EBI, accessed 2026-05-26)
• Open Targets Platform (CC0 1.0, accessed 2026-05-26)
• ClinVar (NCBI, accessed 2026-05-26) — entries at ≥2-star review status
• ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-26)

This page is published by the ExomeDNA Research Team. Last reviewed: 2026-05-26.